Per Stål

Per Stål is an Adjunct Professor at Karolinska Institutet's Department of Medicine, Huddinge, and a Consultant at Karolinska University Hospital. His clinical expertise focuses on chronic liver diseases, particularly hepatocellular carcinoma (HCC) and cirrhosis. He leads the 'Rare metabolic liver diseases, coagulation and hepatocellular carcinoma' research group and teaches the SVK course in Liver and Pancreatic diseases for medical students.

Research Focus

Stål's research centers on improving early HCC detection in cirrhotic patients through biomarker validation (blood proteins, micro-RNA) and exploring immunotherapy approaches for advanced HCC. His work spans translational studies on neoantigens, T-cell therapies, and metabolic drivers of liver cancer. Key areas include:

• Biomarker discovery for hepatocellular carcinoma
• Non-alcoholic fatty liver disease (NAFLD) progression and outcomes
• Iron metabolism disorders in liver disease
• Immunotherapy mechanisms in liver cancer

Publication Trends

His recent articles (2023-2025) demonstrate strong emphasis on:

• Molecular diagnostics (DNA methylation, miRNA, proteomics)
• Clinical outcomes in NAFLD/MASLD cohorts
• Novel immunotherapies and T-cell targeting
• Epidemiology of viral hepatitis-related HCC

with consistent focus on translating basic findings to clinical applications.

Supervision

Current and former PhD students include:

• Sanna Norén (Hemostasis in cirrhosis/HCC)
• Hannes Hegmar (research area unspecified)

Research Group

Co-leads the 'Stål and Wahlin research group' investigating rare metabolic liver diseases, coagulation disorders, and hepatocellular carcinoma pathogenesis through clinical and translational approaches.